WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that TheraCour Pharma, Inc. (TheraCour®), a major shareholder of the Company, completed its programmed sale of shares of NanoViricides, Inc, in December, 2009. The programmed sale under Securities and Exchange Commission Rule 10b5-1 was authorized and initiated in February, 2009.
